Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FAM86C2P is an unprocessed pseudogene annotated as a long noncoding RNA (lncRNA). It is transcribed as a 13.7 kb RNA but not believed to encode a full-length functional protein. This locus may, in rare instances, be translated into a short peptide (131 amino acids), evolutionarily derived from the protein-coding Fam86 gene family, but several internal coding exons were lost through evolution so any peptide product would be truncated and structurally distinct from canonical Fam86 proteins[1][4][7][10]. FAM86C2P is localized to both cytoplasm and nucleus, and its precise function remains poorly understood, but recent studies report a potential tumor-promoting role in high-grade serous ovarian cancer by regulating pathways involving DNA repair (RNASEH2A) and translation (EEF2KMT, its parental homolog)[4]. FAM86C2P does not encode a classical druggable target such as a receptor, enzyme, transporter, or transcription factor, nor are there any known drugs or validated mechanisms targeting this locus. It is best classified as a lncRNA/pseudogene with emerging but very limited functional evidence.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 86 member C2, pseudogene (FAM86C2P).